An invited review following the Soujinkai Award : development of novel chimeric antigen receptor-expressing t cells promoting immune cell infiltration and survival in the tumor tissue

Chimeric Antigen Receptor (CAR) -T cell therapy is attracting the attention for its remarkable therapeutic efficacy on hematological malignancies. Meanwhile, some serious issues currently remain in CAR-T cell therapy, one of which is the ineffectiveness against solid tumors. In order to overcome the issue, we developed the next generation CAR-T cell which simultaneously produce IL-7 and CCL19 (7×19 CAR-T cell). In several solid tumor mouse models, administration of 7 × 19 CAR-T cells induced conspicuous infiltrations of T cells and dendritic cells (DCs) inside the tumor tissues, and exert potent antitumor efficacies in cooperation with the recipient T cells. In addition, a long-term immunological memory against the tumor was formed after the treatment, suggesting that the treatment with 7×19 CAR-T cells enabled the prevention of cancer recurrence. In conclusion, our study concerning the next-generation CAR-T cell is expected to lead an innovative therapy against solid tumors.

solid tumor

T cell　

CAR-T cell

IL-17

CCL19